{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:15:29Z","timestamp":1792818929894,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","aaojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.ophtha.2024.07.008","type":"journal-article","created":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T07:20:52Z","timestamp":1720941652000},"page":"62-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Cardiovascular and Cerebrovascular Adverse Events Associated with Intravitreal Anti-VEGF Monoclonal Antibodies"],"prefix":"10.1016","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5729-2233","authenticated-orcid":false,"given":"Jee Myung","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Yong","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2115-7835","authenticated-orcid":false,"given":"Min Seo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5632-5208","authenticated-orcid":false,"given":"Seung Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1628-9948","authenticated-orcid":false,"given":"Dong Keon","family":"Yon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Il","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2187-196X","authenticated-orcid":false,"given":"Joo Yong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2024.07.008_bib1","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","article-title":"Age-related macular degeneration","volume":"392","author":"Mitchell","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2024.07.008_bib2","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(20)31559-2","article-title":"Retinal vascular occlusions","volume":"396","author":"Scott","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2024.07.008_bib3","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMra1005073","article-title":"Diabetic retinopathy","volume":"366","author":"Antonetti","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2024.07.008_bib4","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Wells","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ophtha.2024.07.008_bib5","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature","volume":"27","author":"Falavarjani","year":"2013","journal-title":"Eye"},{"key":"10.1016\/j.ophtha.2024.07.008_bib6","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","article-title":"Mechanisms of adverse effects of anti-VEGF therapy for cancer","volume":"96","author":"Kamba","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ophtha.2024.07.008_bib7","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1136\/bjophthalmol-2014-305252","article-title":"Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD","volume":"98","author":"Avery","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.07.008_bib8","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1001\/jamaophthalmol.2021.0640","article-title":"Cardiovascular adverse events with intravitreal anti-vascular endothelial growth factor drugs: a systematic review and meta-analysis of randomized clinical trials","volume":"139","author":"Ntjam","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.07.008_bib9","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jamaophthalmol.2014.2333","article-title":"Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: Systematic review and meta-analysis","volume":"132","author":"Thulliez","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.07.008_bib10","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1001\/jamaophthalmol.2018.0002","article-title":"Overview of systematic reviews and meta-analyses on systemic adverse events associated with intravitreal anti\u2013vascular endothelial growth factor medication use","volume":"136","author":"Thulliez","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.07.008_bib11","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"VigiBase, the WHO Global ICSR Database System: basic facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Drug Inf J"},{"key":"10.1016\/j.ophtha.2024.07.008_bib12","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ophtha.2024.07.008_bib13","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.ophtha.2021.05.008","article-title":"Ocular safety profile of BRAF and MEK inhibitors: data from the World Health Organization Pharmacovigilance Database","volume":"128","author":"Mettler","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2024.07.008_bib14","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1093\/eurheartj\/ehab362","article-title":"Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study","volume":"42","author":"Salem","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ophtha.2024.07.008_bib15","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/annrheumdis-2018-214598","article-title":"Drug-induced systemic lupus: revisiting the ever-changing spectrum of the disease using the WHO pharmacovigilance database","volume":"78","author":"Arnaud","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ophtha.2024.07.008_bib16","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.cgh.2021.04.039","article-title":"Hepatobiliary adverse drug reactions associated with remdesivir: The WHO International Pharmacovigilance Study","volume":"19","author":"Kim","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.ophtha.2024.07.008_bib17","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10618-006-0052-8","article-title":"Duplicate detection in adverse drug reaction surveillance","volume":"14","author":"Nor\u00e9n","year":"2007","journal-title":"Data Min Knowl Discov"},{"key":"10.1016\/j.ophtha.2024.07.008_bib18","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw0064","article-title":"Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening","volume":"11","author":"Lin","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ophtha.2024.07.008_bib19","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40264-017-0548-8","article-title":"The power of the case narrative - can it be brought to bear on duplicate detection?","volume":"40","author":"Nor\u00e9n","year":"2017","journal-title":"Drug Saf"},{"key":"10.1016\/j.ophtha.2024.07.008_bib20","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2024.07.008_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101967","article-title":"Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database","volume":"59","author":"Zhou","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ophtha.2024.07.008_bib22","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular toxicities associated with ibrutinib","volume":"74","author":"Salem","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ophtha.2024.07.008_bib23","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jaci.2018.09.001","article-title":"Characterizing drug-induced capillary leak syndromes using the World Health Organization VigiBase","volume":"143","author":"Mertz","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.ophtha.2024.07.008_bib24","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A\u00a0Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ophtha.2024.07.008_bib25","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1530\/EJE-20-0650","article-title":"Atrial fibrillation in patients treated with intravenous zoledronic or pamidronic acid: a pharmacoepidemiological study","volume":"184","author":"Pijnenburg","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ophtha.2024.07.008_bib26","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2353\/ajpath.2006.050834","article-title":"Vascular endothelial growth factor localization in the adult","volume":"168","author":"Maharaj","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ophtha.2024.07.008_bib27","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1200\/JCO.2010.31.9129","article-title":"Congestive heart failure risk in patients with breast cancer treated with bevacizumab","volume":"29","author":"Choueiri","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ophtha.2024.07.008_bib28","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/s41433-018-0021-7","article-title":"Clinical pharmacology of intravitreal anti-VEGF drugs","volume":"32","author":"Fogli","year":"2018","journal-title":"Eye"},{"key":"10.1016\/j.ophtha.2024.07.008_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13256-021-02983-3","article-title":"Hypertensive cerebral hemorrhage with undetectable plasma vascular endothelial growth factor levels in a patient receiving intravitreal injection of aflibercept for bilateral diabetic macular edema: a case report","volume":"15","author":"Yoshimoto","year":"2021","journal-title":"J\u00a0Med Case Rep"},{"key":"10.1016\/j.ophtha.2024.07.008_bib30","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ophtha.2020.07.062","article-title":"Risk of systemic adverse events after intravitreal bevacizumab, ranibizumab, and aflibercept in routine clinical practice","volume":"128","author":"Maloney","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2024.07.008_bib31","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.ophtha.2018.09.040","article-title":"Risk of systemic adverse events associated with intravitreal anti\u2013VEGF therapy for diabetic macular edema in routine clinical practice","volume":"126","author":"Maloney","year":"2019","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2024.07.008_bib32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/jamaophthalmol.2015.4070","article-title":"Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis","volume":"134","author":"Avery","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.07.008_bib33","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1016\/j.ophtha.2016.06.053","article-title":"Introducing anti-vascular endothelial growth factor therapies for AMD did not raise risk of myocardial infarction, stroke, and death","volume":"123","author":"Yashkin","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2024.07.008_bib34","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/jamaophthalmol.2018.6891","article-title":"Association of intravitreal anti-vascular endothelial growth factor therapy with risk of stroke, myocardial infarction, and death in patients with exudative age-related macular degeneration","volume":"137","author":"Dalvin","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.07.008_bib35","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1016\/j.jacc.2020.02.070","article-title":"Cardiac Events Associated with Chimeric Antigen Receptor T-Cells (CAR-T): a VigiBase perspective","volume":"75","author":"Salem","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ophtha.2024.07.008_bib36","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2337\/dc10-1771","article-title":"Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase","volume":"34","author":"Willemen","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ophtha.2024.07.008_bib37","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-217018","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO\u2019s adverse drug reactions database","volume":"81","author":"Nguyen","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ophtha.2024.07.008_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102707","article-title":"Drug-induced IgA vasculitis in children and adults: revisiting drug causality using a dual pharmacovigilance-based approach","volume":"20","author":"Rasmussen","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ophtha.2024.07.008_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/annrheumdis-2018-213470","article-title":"Checkpoint inhibitor-associated immune arthritis","volume":"78","author":"Arnaud","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ophtha.2024.07.008_bib40","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1001\/jamaophthalmol.2017.0455","article-title":"Vascular safety of ranibizumab in patients with diabetic macular edema: a pooled analysis of patient-level data from randomized clinical trials","volume":"135","author":"Zarbin","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.07.008_bib41","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1097\/IAE.0000000000001084","article-title":"Intravitreal ranibizumab therapy for neovascular age-related macular degeneration and the risk of stroke: a national sample cohort study","volume":"36","author":"Rim","year":"2016","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2024.07.008_bib42","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1161\/01.RES.76.5.758","article-title":"Regulation of vascular endothelial growth factor in cardiac myocytes","volume":"76","author":"Levy","year":"1995","journal-title":"Circ Res"},{"key":"10.1016\/j.ophtha.2024.07.008_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100338","article-title":"Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management","volume":"7","author":"Vallerio","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ophtha.2024.07.008_bib44","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.ymthe.2020.03.011","article-title":"Susceptibility to cardiac arrhythmias and sympathetic nerve growth in VEGF-B overexpressing myocardium","volume":"28","author":"L\u00e4hteenvuo","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.ophtha.2024.07.008_bib45","article-title":"Inhibitory effect of vascular endothelial growth factor on the slowly activating delayed rectifier potassium current in guinea pig ventricular myocytes","volume":"7","author":"Lin","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.ophtha.2024.07.008_bib46","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1001\/jamaophthalmol.2018.4892","article-title":"Association of intravitreal injections with blood pressure increase: The Following Excitement and Anxiety Response under Intravitreal Injection Study","volume":"137","author":"Berger","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.07.008_bib47","article-title":"Is perioperative blood pressure monitoring during intravitreal injections important?","volume":"14","author":"Debbarma","year":"2022","journal-title":"Ther Adv Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.07.008_bib48","doi-asserted-by":"crossref","DOI":"10.1080\/21688370.2016.1143544","article-title":"Heterogeneity of the blood-brain barrier","volume":"4","author":"Wilhelm","year":"2016","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.ophtha.2024.07.008_bib49","doi-asserted-by":"crossref","first-page":"23618","DOI":"10.1073\/pnas.1912409116","article-title":"The in\u00a0vivo endothelial cell translatome is highly heterogeneous across vascular beds","volume":"116","author":"Cleuren","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ophtha.2024.07.008_bib50","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nature25739","article-title":"A\u00a0molecular atlas of cell types and zonation in the brain vasculature","volume":"554","author":"Vanlandewijck","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ophtha.2024.07.008_bib51","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1172\/JCI76431","article-title":"Canonical WNT signaling components in vascular development and barrier formation","volume":"124","author":"Zhou","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.ophtha.2024.07.008_bib52","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1161\/CIRCRESAHA.119.316476","article-title":"Dll4 suppresses transcytosis for arterial blood-retinal barrier homeostasis","volume":"126","author":"Yang","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.ophtha.2024.07.008_bib53","doi-asserted-by":"crossref","first-page":"E11827","DOI":"10.1073\/pnas.1813217115","article-title":"Interplay of the Norrin and Wnt7a\/Wnt7b signaling systems in blood\u2013brain barrier and blood\u2013retina barrier development and maintenance","volume":"115","author":"Wang","year":"2018","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.ophtha.2024.07.008_bib54","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.molmed.2010.07.003","article-title":"The Norrin\/Frizzled4 signaling pathway in retinal vascular development and disease","volume":"16","author":"Ye","year":"2010","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.ophtha.2024.07.008_bib55","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1161\/STROKEAHA.112.654632","article-title":"Age-related macular degeneration and long-term risk of stroke subtypes","volume":"43","author":"Ikram","year":"2012","journal-title":"Stroke"},{"key":"10.1016\/j.ophtha.2024.07.008_bib56","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1136\/bjophthalmol-2013-303844","article-title":"What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?","volume":"98","author":"Avery","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.07.008_bib57","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/bjophthalmol-2020-316373","article-title":"Cardiovascular risk in patients receiving ranibizumab for exudative age-related macular degeneration: a nationwide self-controlled case-series study","volume":"105","author":"Jeon","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2024.07.008_bib58","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ophtha.2008.09.046","article-title":"Cerebrovascular accidents in ranibizumab","volume":"116","author":"Ueta","year":"2009","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2024.07.008_bib59","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1016\/j.ophtha.2013.09.020","article-title":"Is there risk of stroke with aflibercept?","volume":"121","author":"Beaumont","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2024.07.008_bib60","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/jmv.27424","article-title":"Comparative safety of mRNA COVID-19 vaccines to influenza vaccines: a pharmacovigilance analysis using WHO international database","volume":"94","author":"Kim","year":"2022","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.ophtha.2024.07.008_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-27631-8","article-title":"Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database","volume":"13","author":"Nguyen","year":"2022","journal-title":"Nat Commun"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642024004196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642024004196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T07:43:48Z","timestamp":1734507828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642024004196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0161642024004196"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2024.07.008","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular and Cerebrovascular Adverse Events Associated with Intravitreal Anti-VEGF Monoclonal Antibodies","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2024.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}